Gilead Sciences (GILD -1.7%) has completed its rolling marketing application to the FDA seeking full approval of Veklury (remdesivir) for the treatment of severely ill hospitalized COVID-19 patients. It initiated the process on April 8.
The FDA approved the emergency use of the antiviral for these patients on May 1. It remains the only medicine to receive the nod in the U.S. to date. It is also available in Europe, Japan, India, Australia and Canada.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.